Investing in Stocks Made Easy!
at ₹0 Brokerage with 5paisa.
+91
By proceeding, you agree to all T&C*
Investing in Stocks Made Easy!
We've sent a 6-digit verification code to +91 99123918232
Didn't receive the code? Resend
VINEETLAB

Vineet Laboratories Share Price

 

 

Vineet Laboratories live price: ₹35.04. It opened at ₹33 vs previous close ₹33; intraday high/low: ₹35/₹32. The 50 & 200 DMA stand at ₹31.50/₹32.82.

Vineet Laboratories Performance

  • Today's Low
  • ₹32
  • Today's High
  • ₹35
  • 52 Week Low
  • ₹22
  • 52 Week High
  • ₹42
  • Open Price₹33
  • Previous Close₹33
  • Volume189,959
  • 50 DMA₹31.50
  • 100 DMA₹32.08
  • 200 DMA₹32.82

Vineet Laboratories Chart

Investment Returns

  • Over 1 Month + 20.79%
  • Over 3 Month + 7.52%
  • Over 6 Month + 0.83%
  • Over 1 Year + 26.82%

Smart Investing Starts Here Start SIP with Vineet Laboratories for Steady Growth!

Invest Now

Vineet Laboratories Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -6.6
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 67
  • P/B Ratio
  • 2.7
  • Average True Range
  • 1.75
  • EPS
  • 0
  • Dividend Yield
  • 0
  • MACD Signal
  • 0.25
  • RSI
  • 70.06
  • MFI
  • 77.62

Vineet Laboratories Financials

Vineet Laboratories Technicals

EMA & SMA

Current Price
₹35.04
+ 2.24 (6.83%)
pointer
  • Bearish Moving Average 0
  • Bullish Moving Average 16
  • 20 Day
  • ₹31.54
  • 50 Day
  • ₹31.50
  • 100 Day
  • ₹32.08
  • 200 Day
  • ₹32.82

Resistance and Support

33.97 Pivot Speed
  • R3 40.33
  • R2 37.85
  • R1 36.45
  • S1 32.57
  • S2 30.09
  • S3 28.69

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Vineet Laboratories has an operating revenue of Rs. 54.59 Cr. on a trailing 12-month basis. An annual revenue de-growth of -49% needs improvement, Pre-tax margin of -28% needs improvement, ROE of -137% is poor and needs improvement. The company has a reasonable debt to equity of 26%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 200DMA and around 6% above its 50DMA. It needs to stay above the 200DMA levels to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 22% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 77 which is FAIR indicating the recent price performance, Buyer Demand at D which indicates heavy supply, Group Rank of 54 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Vineet Laboratories Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-14 Quarterly Results
2025-11-27 Right issue of Equity Shares
2025-11-08 Quarterly Results
2025-07-22 Quarterly Results
2025-05-12 Audited Results
Date Purpose Remarks
2022-09-20 FINAL Rs.1.00 per share(10%)Final Dividend
View Vineet Laboratories Dividend History Arrow

Vineet Laboratories F&O

Vineet Laboratories Shareholding Pattern

12.46%
82.41%
5.13%

Vineet Laboratories FAQs

Vineet Laboratories share price is ₹35 As on 18 April, 2026 | 14:42

The Market Cap of Vineet Laboratories is ₹67.3 Cr As on 18 April, 2026 | 14:42

The P/E ratio of Vineet Laboratories is -6.6 As on 18 April, 2026 | 14:42

The PB ratio of Vineet Laboratories is 2.7 As on 18 April, 2026 | 14:42

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23